12497211

Source:http://linkedlifedata.com/resource/pubmed/id/12497211

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0010711, umls-concept:C0020789, umls-concept:C0023467, umls-concept:C0030705, umls-concept:C0031928, umls-concept:C0040808, umls-concept:C0205195, umls-concept:C0205225, umls-concept:C0332325, umls-concept:C0876099
pubmed:issue	1
pubmed:dateCreated	2002-12-23
pubmed:abstractText	Mylotarg has moderate activity as a single agent in patients with CD33-positive refractory or relapsed acute myelogenous leukemia (AML). A combination of an anthracycline and cytarabine (ara-C) is the core of most AML induction regimens. We conducted a pilot study of Mylotarg combined with idarubicin and ara-C in patients with refractory or relapsed AML.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7806519
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Aminoglycosides, http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine, http://linkedlifedata.com/resource/pubmed/chemical/Idarubicin, http://linkedlifedata.com/resource/pubmed/chemical/gemtuzumab
pubmed:status	MEDLINE
pubmed:month	Jan
pubmed:issn	0344-5704
pubmed:author	pubmed-author:AlvaradoYesidY, pubmed-author:CortesJorgeJ, pubmed-author:EsteyElihuE, pubmed-author:FaderlStefanS, pubmed-author:Garcia-ManeroGuillermoG, pubmed-author:GilesFrancis JFJ, pubmed-author:KantarjianHagopH, pubmed-author:ThomasDeborahD, pubmed-author:TsimberidouApostoliaA
pubmed:issnType	Print
pubmed:volume	51
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	87-90
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:12497211-Adult, pubmed-meshheading:12497211-Aged, pubmed-meshheading:12497211-Aminoglycosides, pubmed-meshheading:12497211-Anti-Bacterial Agents, pubmed-meshheading:12497211-Antibodies, Monoclonal, pubmed-meshheading:12497211-Antibodies, Monoclonal, Humanized, pubmed-meshheading:12497211-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12497211-Cytarabine, pubmed-meshheading:12497211-Drug Resistance, Neoplasm, pubmed-meshheading:12497211-Female, pubmed-meshheading:12497211-Hepatic Veno-Occlusive Disease, pubmed-meshheading:12497211-Humans, pubmed-meshheading:12497211-Idarubicin, pubmed-meshheading:12497211-Leukemia, Myeloid, Acute, pubmed-meshheading:12497211-Male, pubmed-meshheading:12497211-Middle Aged, pubmed-meshheading:12497211-Pilot Projects, pubmed-meshheading:12497211-Recurrence
pubmed:year	2003
pubmed:articleTitle	Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
pubmed:affiliation	Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA.
pubmed:publicationType	Journal Article